### Alert
Increased risk of fever when pneumococcal conjugate vaccine concurrently administered with other vaccines. Prophylactic administration of paracetamol at the time of, or immediately after, vaccination to reduce the risk of fever is not recommended. However, if an infant has a fever of > 38.5°C following vaccination or has pain at the injection site, and is miserable, paracetamol can be given. The dose of paracetamol is 15 mg/kg/dose, up to a maximum dose of 60 mg/kg per day in four divided doses.

### Indication
1. Primary immunisation against pneumococcal disease in infants at 6 weeks/2 months, 4 and 6 months of age. 2. Booster dose at 12 months in at risk children:
   - Indigenous children in Northern Territory, Queensland, South Australia or Western Australia.
   - Children with a medical condition associated with an increased risk of invasive pneumococcal disease.
   - Preterm infants < 28 weeks gestation
3. Catch-up vaccination schedules in children up to 5 years of age.

### Action
Induces the production of antibodies against *Streptococcus pneumoniae*.

### Drug Type
Vaccine
Conjugated pneumococcal vaccine composed of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F each conjugated to CRM197 carrier protein.

### Trade Name
Prevenar 13.

### Presentation
Suspension in pre-filled syringe.

### Dosage/Interval
0.5 mL.

### Route
IM

### Administration
1. May administer oral sucrose 2 minutes prior to injection (observe local pain policy).
2. Shake syringe vigorously immediately prior to use to obtain an homogenous, white suspension.
3. Administer 0.5 ml of suspension by intramuscular injection (IMI) to the anterolateral aspect of the thigh (slowly to reduce pain).
4. Administer on the opposite limb from other concurrently administered vaccines (e.g. INFANRIX hexa).

### Monitoring
1. Observe for 15 minutes after vaccination for any Adverse Event Following Immunisation (AEFI).
2. Pain: Refer to local pain relief policy.
4. Infants with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post-vaccination.

### Contraindications
- Anaphylaxis following a previous dose of pneumococcal vaccine.
- Hypersensitivity to any vaccine component.

### Precautions
- Significant acute illness or temperature greater than 38.5°C – postpone vaccine until neonatologist approves.
- Immunosuppressed patients

### Drug Interactions
N/A

### Adverse Reactions
Common (1–10%): Pain, inflammation, redness, swelling, injection site mass persisting for up to a few days.
Uncommon (0.1–< 1%): Headache, fever, lethargy, malaise, myalgia, irritability, restlessness, diarrhoea, vomiting.
Any serious or unexpected adverse event following immunisation should be promptly reported. Providers should use clinical judgment in deciding which adverse events to report and parents/carers should be encouraged to notify the immunisation service provider or health authorities of any untoward medical occurrence that follows immunisation. Each State/Territory has its own contact details for notification. Contact telephone number for NSW Public Health Unit is 1300 066 055.

### Compatibility
Do not mix with any other vaccines in the same syringe.
### Stability
Should be injected promptly.
However, the vaccine stable for up to eight hours at room temperature.

### Storage
Store between 2 and 8°C.
Do NOT freeze.

### Special Comments
1. There are two different kinds of pneumococcal vaccines — pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccine (PPVs). PCVs are vaccines based on chemical coupling of *S. pneumoniae* to an immunogenic protein carrier, which enhances antibody response and induces immune memory in young infants as opposed to PPVs which are associated with poor immunogenicity in children < 2 years.
2. PCV vaccines vary in the number of pneumococcal serotypes included and the proteins used for conjugation.
3. Prevenar 13 is the 13vPCV that has been registered in Australia since 2010 and used in the National Immunisation Program since July 2011.
4. Completion of a primary course of PCV with the same formulation is generally preferred — however if vaccination has commenced with a 10vPCV (e.g. overseas), completion of the course with a 13vPCV is acceptable. Refer to The Australian Immunisation Handbook.

### Evidence summary
As per NMF Consensus Group. Refer to reference manual or electronic version.

### References
As per NMF Consensus Group. Refer to reference manual or electronic version.